The following clinical trial alerts were issued by Cystic Fibrosis Foundation in August 2021.
August 2, 2021
Status: Enrolling
Description: This study is testing inhaled AR-501, a drug intended to treat infections in the lung. The study will measure the drug’s safety, how well it works, and how the body processes it. Multiple doses of AR-501 will be tested in both healthy adults and adults with cystic fibrosis who are infected with Pseudomonas aeruginosa to find the best dose.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 45% or greater
Number of Visits: 11
Length of Participation: 6 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03669614
August 23, 2021
Study to evaluate VX-121 in adults 18 years and older with cystic fibrosis
Status: Completed with results
Description: This study evaluated the safety, tolerability, and effectiveness of three different doses of the drug VX-121 in triple combination with tezacaftor (TEZ) and VX-561 (deuterated ivacaftor) in people with cystic fibrosis who have two copies of the F508del mutation or one copy of the F508del mutation and one minimal function mutation.
Age: 18 Years and Older
Mutation: Two Copies F508del or One Copy F508del
Fev1% Predicted: 40 to 90%
Number of Visits: 10
Length of Participation: 17 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03912233